Article
A histone deacetylase-dependent screen in yeast.
Bioorganic & medicinal chemistry - 1 Nov 2010
Weerasinghe Sujith V W, Wambua Magdalene, Pflum Mary Kay H
Abstract excerpt
Histone deacetylase (HDAC) proteins are promising targets for cancer treatment, as shown by the recent FDA approval of the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA, Vorinostat) for the treatment of cutaneous T-cell lymphoma. To identify additional potent inhibitors and characterize HDAC mutant proteins, there is interest to develop an inexpensive screening method dependent on native substrates. Here,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
